Purpose: Lung adenocarcinoma and lung squamous cell carcinoma (SCC) are the most common non-small cell lung cancer (NSCLC) subtypes. This study was designed to determine whether reduced expression of TGFb type II receptor (TGFbRII) promotes lung adenocarcinoma and SCC carcinogenesis.
Introduction
Although more than 175,000 cases of non-small cell lung cancer (NSCLC) are diagnosed annually in the United States, the 5-year survival rate remains less than 20% (1) . Lung adenocarcinoma and lung squamous cell carcinoma (SCC) are the most common histologic subtypes and although most ($85%) lung cancer is smoking-related, lung SCC is more strongly associated with smoking exposure (2) . It is hypothesized that lung adenocarcinoma arises from the distal airway epithelial progenitor (3), whereas lung SCC arises from the keratin-positive basal cell population that contains the upper airway epithelial progenitor (4) . TGFb is a multifunctional cytokine that promotes epithelial differentiation and inhibits cell growth (5) and defective TGFb signaling is often associated with more aggressive tumor behavior (6) . TGFb binds a heterodimer of TGFb type I and type II receptors (TGFbRI and TGFbRII) that signal by phosphorylating Smad family transcription factors (5) .
In previous small studies with poorly defined patient populations, reduced TGFbRII expression was reported in 40% to 80% of NSCLC at the protein and/or mRNA level (7) (8) (9) . Although TGFbRII mutations are uncommon (10) , both microsatellite instability and promoter methylation have been associated with reduced TGFbRII expression (8, 11) . From these studies, it is unknown whether reduced TGFbRII expression in human NSCLC is associated with specific histologic subtypes, more aggressive tumor behavior, or reduced patient survival. In lung cancer cell lines, TGFbRII restoration reduces proliferation, anchorage-independent growth, and xenograft growth (7) whereas TGFbRII knockdown increases Transwell migration (12) . In mouse models, TGFbRII deletion promotes the development of oncogene-initiated malignancies in the pancreas, colon, breast, and oral epithelium (13) (14) (15) (16) , and a recent study shows that TGFbRII loss increases the invasiveness of Krasinitiated lung adenocarcinomas (17) . However, because most lung cancer mouse models produce predominantly, if not exclusively, adenomas and adenocarcinomas (18) , it is unknown whether TGFb signaling disruption affects development of other NSCLC subtypes.
In this study, we evaluated TGFbRII expression at the protein and mRNA level in a large number of human NSCLC samples and show that reduced TGFbRII expression is associated with more aggressive tumor behavior, including reduced tumor differentiation, higher tumor stage, increased nodal metastases, and reduced survival. To generate a model that can produce lung SCCs and to determine whether TGFbRII loss initiates or promotes lung carcinogenesis, we targeted TGFbRII deletion to the conducting airway epithelium with the keratin-5 Cre Ã PR transgene (K5Cre Ã PR; ref. 19 ). The K5 promoter targets the multipotent basal cell progenitor of the upper airway (20) . Cre Ã PR is a humanized Cre recombinase progesterone receptor (Cre Ã PR) fusion protein that can be activated by RU486 but has low ligand-independent activity (21) . Tracheal RU486 activates Cre Ã PR in sporadic airway epithelial cells (21) , hence oncogenic alterations driven by this construct allow for the clonal expansion of cells with somatic mutations, analogous to what occurs in human cancer. Using this system, we show that TGFbRII deletion markedly promotes the development of Kras-initiated lung tumors, indicating that TGFbRII loss plays a causal role during lung carcinogenesis. Our studies in human samples show that reduced TGFbRII expression is a negative prognostic marker in lung cancer.
Materials and Methods

NSCLC samples
After Institutional Review Board (IRB) approval, 38 NSCLC samples were obtained from the Oregon Health & Sciences University (OHSU; Portland, OR) Department of Pathology Tumor Bank. Demographic and pathologic data were recorded when banked; histology and grade were confirmed by a second pathologist (S. White). RNA was extracted from13 corresponding frozen samples. We also purchased a tissue microarray (T8235724, lot A606098; BioChain) composed of 64 NSCLC sections with accompanying demographic and pathologic data. With IRB approval, 85 NSCLC samples were obtained from the Colorado Lung SPORE Tissue Bank Core. Pathologic diagnosis of these samples was confirmed by a second pathologist (W. Franklin). Additional clinical and pathologic data were extracted from pathology reports and medical records; survival data were obtained by searching the social security death index (SSDI) database. Of these samples, 77 had paraffin blocks available for immunostaining and 37 had matched tumor and nonmalignant lung RNA available for analysis.
Immunostaining and quantitative reverse transciptase PCR of human NSCLC samples
Immunostaining was conducted as previously described (14) with anti-TGFbRII antibody (1:200; Santa Cruz C16) and staining intensity was graded as 3þ (intensity greater than normal airway), 2þ (equal to normal airway), 1þ (reduced compared with normal airway), or 0 (absent) by 2 independent observers (S.P. Malkoski and S.M. Haeger). Because of the low frequency of samples with increased (3þ) or absent (0) staining, samples were grouped as having preserved (2þ or 3þ) or reduced (0 or 1þ) staining for analysis. Immunostaining for lymphocytes and macrophages was conducted with anti-CD3 antibody (Abcam #5690 at 1:250) and anti-MAC387 (Abcam #22506 at 1:200). Staining was quantified by counting the number of positive cells on 4 random 10Â fields in at least 24 independent human NSCLC samples. RNA was harvested by homogenization in RNAzol (Invitrogen) and then purification with RNeasy columns (Qiagen). Quantitative reverse transcriptase PCR (qRT-PCR) was carried out with the Brilliant II Kit (Stratagene) using a GAPDH (glyceraldehyde-3-phosphate dehydrogenase) internal control and TaqMan probe Hs00559657 (Applied Biosystems) on an ABI 7900 thermal cycler. Data were analyzed by the DDC t method and expressed as fold reduction compared with paired nonmalignant lung. When paired nonmalignant
Translational Relevance
Although lung cancer is a common malignancy, the 5-year survival remains low, illustrating a need for an improved understanding of basic molecular mechanisms that can subsequently be translated into novel therapeutic strategies. In this study, we found that reduced TGFb type II receptor (TGFbRII) expression in human non-small cell lung cancer (NSCLC) samples is associated with more aggressive tumor behavior and reduced patient survival. Our mouse model shows that TGFbRII deletion in sporadic airway epithelial cells promotes formation of both adenocarcinomas and squamous carcinomas, supporting a causal role of TGFbRII loss in lung carcinogenesis and suggesting that reduced TGFbRII expression is a negative prognostic marker in lung cancer. Our mouse model will be a useful resource for testing novel therapeutic approaches directed toward NSCLC with reduced TGFbRII expression.
lung was unavailable, expression in tumor samples was compared with grouped nonmalignant samples run on the same plate. Differences in immunostaining frequency between groups were analyzed by a c 2 or Fisher exact test, depending on the expected frequency values. Differences in mRNA expression between groups were analyzed by nonparametric methods (Mann-Whitney or Kruskal-Wallis). Survival curves were obtained using the Kaplan-Meier method, and comparisons across groups were made with log-rank and stratified log-rank tests. Analyses were conducted with Prism5 (GraphPad) and SAS version 9.2 (SAS Institute, Inc.).
NSCLC mouse model
All animal studies were Institutional Animal Care and Use Committee (IACUC)-approved. The TGFbRII conditional allele, lox-stop-lox-Kras G12D conditional allele, and K5Cre Ã PR transgene have been previously described (16, 19, 22, 23) . Mice were treated with tracheal RU486 (500 mg in 25 mL 10% acetone/90% sesame oil) between 4 and 6 weeks of age as previously described (21) . Mice were monitored weekly and euthanized at 1 year of age or if they lost more than 15% of their body weight. When euthanized, a blood sample was collected by cardiac puncture, tumors were enumerated and measured, and a bronchioalveolar lavage (BAL) sample was collected by instillation of two 1-mL aliquots of sterile PBS. The left lung was inflated with 10% formalin and then paraffin-embedded. Blood was allowed to clot and then serum isolated by centrifugation (5,900 Â g, 15 0 , 25 C) and stored at À80 C. After 300 mL of BAL was cytospun (500 rpm, 5 0 , 25 C) onto a slide, remaining BAL cells were separated by centrifugation (5,900 Â g, 15 0 , 25 C) and BAL supernatant stored at À80 C. BAL cells in four 40Â objectives were scored by morphologic criteria, and differences between genotypes compared by unpaired t tests.
Analysis of mouse NSCLC
Lung tumors were separated from grossly normal lung and DNA extracted with the DNeasy Kit (Qiagen); PCR for the recombinant TGFbRII allele was carried out as previously described (16) . RNA extraction, qRT-PCR, and TGFbRII immunohistochemistry were conducted as described above. Total TGFb1 in BAL and serum was quantified by ELISA after acid activation per the manufacturer's instructions (R&D Systems), and differences between groups were compared by one-way ANOVA or unpaired t test. Lesions were classified as atypical adenomatous hyperplasia (AAH), adenoma, adenocarcinoma, or squamous carcinoma on hematoxylin and eosin sections by 2 investigators (S.P. Malkoski and S.M. Haeger) using previously described criteria (24) with independent confirmation by a pathologist (D. Merrick) on a subset ($10%) of lesions. Tumors were immunostained with antibodies against K5 (1:1,000; Abcam #53121) and thyroid transcription factor (TTF, 1:100; Abcam #40880) to further confirm histologic subtype. Images were acquired on a Nikon Eclipse 80i and analyzed with Nikon Elements Software.
Lesions were quantified per lung section and per mm 2 lung and differences compared by one-way ANOVA or unpaired t test. Immunostaining for proliferating cell nuclear antigen (PCNA, 1:100; Santa Cruz SC-56) and leukocytes (1:500 anti-CD3; Abcam #5690) was conducted as described above and quantified by counting the number of positive cells per tumor area.
Migration and invasion assays in Beas2b cells with TGFbRII knockdown
Beas2B human bronchial epithelial cells (American Type Culture Collection) were cultured in BEGM basal media supplemented with BEGM SingleQuot growth factors (Lonza) under standard conditions. Experiments were carried out between the 50th and 65th passages. A stable TGFbRII knockdown line was produced by transfecting the pcPURþU6 plasmid containing the short hairpin RNA (shRNA) against TGFbRII (25) with the pcPURþU6 cassette as a control (iGene Therapeutics). Cells were transfected at 60% confluence with 16 mg/mL plasmid DNA and 40 mL/mL Lipofectamine 2000 (Invitrogen); 48 hours posttransfection, puromycin (1.0 mg/mL; Invivogen) selection was initiated. TGFbRII knockdown was confirmed by quantitative PCR (qPCR) and Western blotting against TGFbRII (1:200; SC400 Santa Cruz Biotechnology) with GAPDH (1:40,000; Abcam #8245) control. Scratch assays were conducted by seeding 4 Â 10 5 cells into 6-well plates, allowing cells to grow to confluence and then wounding with a P200 pipette tip. Wounds were photographed at 0 and 24 hours and wound closure quantified as a percentage of the original wound area (26) . Transwell assays were conducted using 200 mL Blindwell Boyden chambers (50-mm 2 area) and polyvinyl pyrrolidone-free polycarbonate membranes with 12-mm pores (Neuro Probe; ref. 27 ). Migration membranes were coated with 0.01% porcine gelatin; invasion membranes were coated with 5% growth factor-reduced Matrigel (BD Biosciences). Media conditioned for 24 hours with 3T3 cells were used as a chemoattractant in the lower chamber and 3.5 Â 10 4 cells were seeded into the upper chamber. After 24 hours, nonmigrating cells were removed, membranes were fixed, stained with Diff-Quik (Siemens Healthcare Diagnostics Inc.), and photographed at 100Â. Cells from 5 fields of view per insert were counted, experiments were repeated 5 times, and differences between groups were compared by unpaired t tests.
Results
Reduced TGFbRII expression is more common in males, smokers, and lung SCC Reduced TGFbRII expression has been previously reported in a small study with limited demographic data (7). We analyzed TGFbRII expression in 187 NSCLC samples (full demographic data shown in Supplementary Table S1) using a combination of immunostaining and qRT-PCR. Immunostaining was conducted on 172 of 187 samples and each sample was scored as having either preserved (intensity equal to or greater than normal airway) or reduced (intensity less than 50% of normal airway in at least 50% of cells) immunostaining. mRNA expression was analyzed in 48 of 187 samples and was compared with TGFbRII expression in either paired nonmalignant lung (37 of 48 samples) or grouped nonmalignant lung (11 of 48 samples). In Figs. 1 and 2, immunostaining data are expressed as the fraction (%) of NSCLC samples with reduced staining and mRNA expression data are expressed as fold reduction of TGFbRII expression compared with nonmalignant lung. We found that 45% of NSCLC samples had reduced TGFbRII immunostaining and that samples with reduced TGFbRII immunostaining also had reduced TGFbRII mRNA expression (Fig. 1A) . Although reduced TGFbRII immunostaining was somewhat more common in males and smokers, this did not reach statistical significance (Fig. 1B and C, top) ; in contrast, both males and smokers had significantly reduced TGFbRII mRNA expression (Fig.  1B and C, bottom) and the degree of reduced TGFbRII expression was weakly correlated with smoking exposure (Supplementary Fig. S1 ). Interestingly, reduced TGFbRII immunostaining and mRNA expression were markedly more common in SCCs compared with adenocarcinomas (Fig. 1D) . Reduced TGFbRII expression is associated with more aggressive NSCLC behavior Although reduced TGFbRII immunostaining or expression has been associated with increased invasion in human lung adenocarcinoma (12, 17) and more aggressive tumor behavior in other human malignancies (28) (29) (30) , the relationship between reduced TGFbRII expression and clinical tumor behavior in human NSCLC has not been defined. We found that reduced TGFbRII immunostaining and mRNA expression were more common in more poorly differentiated tumors ( Fig. 2A) , tumors with higher tumor (T) stage (Fig. 2B) , and tumors with nodal metastases (Fig. 2C) . Interestingly, there was no association between the degree of reduced TGFbRII mRNA expression and tumor size as a continuous variable (not shown), suggesting that reduced TGFbRII expression with higher tumor stage may be driven more by the invasive parameters that dictate clinical tumor stage (e.g., invasion) as opposed to size. Because tumor stage and nodal status dictate overall clinical stage, reduced TGFbRII immunostaining was also more common with increasing clinical stage (not shown) and reduced TGFbRII immunostaining was associated with reduced overall survival in NSCLC (Fig. 2D) . After adjusting for stage in a Cox proportional hazards survival model, preserved TGFbRII immunostaining remained associated with improved survival with an HR of 0.49 [95% confidence interval (CI), 0.24-0.98; P ¼ 0.04].
TGFbRII deletion promotes growth and multiplicity of Kras-induced NSCLC TGFbRII deletion promotes development and malignant conversion of Kras-initiated tumors in both oral epithelium (14) and pancreas (13) . To address the role of TGFbRII loss in lung cancer development in vivo, we developed a mouse model combining TGFbRII deletion with oncogenic Kras G12D activation. We used the K5Cre Ã PR transgene that contains an RU486-inducible Cre recombinase (19) and tracheal RU486 to direct TGFbRII deletion (16) and oncogenic Kras G12D (22) activation to the airways (21) . As expected, the recombinant TGFbRII allele could be detected in tumors but not in adjacent grossly normal lung (Fig. 3A) and TGFbRII immunostaining was reduced in tumors with TGFbRII deletion (hereafter referred to as Kras.TGFbRII þ/À and Kras.
TGFbRII À/À ) compared with Kras tumors (Fig. 3B ). In addition, TGFbRII mRNA expression in whole lung homogenate negatively correlated with increasing tumor burden (Fig. 3C Table S2 ). Kras animals typically developed 2 to 3 tumors per animal; deletion of one or both TGFbRII alleles increased tumor multiplicity by approximately 10-fold (Fig. 4A ) and also increased overall tumor size (Supplementary Fig. S2) . Because of the increased number of small tumors with TGFbRII deletion, we analyzed the largest single tumor in each animal to assess the effect of TGFbRII deletion on established tumor growth (Fig.  4B) ; this analysis showed that TGFbRII deletion increased the growth of established Kras-initiated lung tumors. Although there was a low level of tumor formation in vehicle-treated Kras.TGFbRII À/À animals, there was a clear, dose-dependent increase in tumor formation with increasing tracheal RU486 dose (Supplementary Table S2 ). These data show that the K5Cre Ã PR transgene can be used for lung targeting and that TGFbRII deletion greatly increases both the number and size of Kras-initiated lung tumors.
Kras.TGFbRII
À/À mice develop both adenocarcinomas and SCCs In our mouse model that uses a K5 promoter and tracheal RU486 to target our genetic manipulations (19, 21) , we observed the formation of both adenocarcinomas and SCCs. Adenocarcinomas displayed typical glandular morphology and stained negative for K5 and positive for TTF, whereas SCCs displayed keratinization and intercellular bridges and were K5-positive and TTF-negative ( Supplementary Fig. S3 ). To analyze the effect of TGFbRII deletion on the formation of specific tumor types, we classified individual lesions according to consensus recommendations (24) and found that TGFbRII deletion increased the number of both benign (AAH and adenomas) and malignant (adenocarcinoma and SCC) lesions ( 
TGFbRII deletion increases proliferation and inflammation in vivo
Because TGFb signaling inhibits epithelial proliferation (5), we compared proliferation in Kras and Kras. TGFbRII À/À tumors and found that Kras.TGFbRII
tumors had a 5-fold increase in staining for the proliferation marker PCNA (Fig. 5A and immunostaining example shown in Supplementary Fig. S4A ). Loss of functional TGFb signaling can cause a compensatory increase in TGFb1 ligand production (14, 31) which can then promote tumor development through increased angiogenesis and inflammation in the tumor microenvironment (14, 32, 33) . We found that TGFbRII deletion increased TGFb1 ligand in the BAL fluid (Fig. 5B) and that increasing tumor burden correlated with higher BAL TGFb1 (Supplementary Fig.  S4B ). TGFbRII deletion was also associated with increased serum TGFb1 ligand levels (not shown) similar to the increased serum TGFb1 levels reported in humans with NSCLC (34) . Similarly, TGFbRII knockdown in human Beas2B cells increased TGFb1 ligand production (Supplementary Fig. S5C ). We did not find increased angiogenesis in TGFbRII À/À lung tumors (not shown) but observed that TGFbRII deletion increased the number of macrophages, lymphocytes, and neutrophils in the BAL (Fig.  5C ) and that the BAL macrophage count correlated with increasing tumor burden ( Supplementary Fig. S4C ). In addition, compared with Kras tumors, Kras.TGFbRII
tumors had increased infiltration of CD3 þ lymphocytes (Fig. 5D , immunostaining example shown in Supplementary Fig. S4D ). To determine whether a similar relationship between reduced TGFbRII expression and increased inflammation exists in human lung cancer, we immunostained human NSCLC samples for both lymphocytes and Fig. S6 ). In sum, these data show that TGFbRII deletion in a murine lung cancer model increases both proliferation and local inflammation and human lung cancer with reduced TGFbRII expression also have increased inflammation.
TGFbRII knockdown in bronchial epithelial cells increases migration and invasion That reduced TGFbRII expression was associated with both increased aggressiveness of human NSCLC and progression of murine lung tumors prompted us to assess whether TGFbRII knockdown promotes cell migration and invasion in vitro. We stably knocked down TGFbRII in a human bronchial epithelial cell line (Beas2B) using an shRNA approach (25) and achieved reduced TGFbRII expression at both the RNA and protein level (Supplementary Fig. S5A ). Interestingly, TGFbRII knockdown did not affect proliferation of Beas2B cells (Supplementary Fig.  S5D ), potentially because these cells are SV40 T antigen immortalized and hence not sensitive to TGFb-mediated growth inhibition. In a scratch assay, TGFbRII knockdown increased in vitro wound closure by almost 3-fold ( Fig. 6A  and B) . In a Matrigel Transwell invasion assay, TGFbRII knockdown increased migration by approximately 2-fold and invasion by approximately 3-fold ( Fig. 6C and D) . These data suggest that increased lung tumor aggressiveness in tumors with reduced TGFbRII expression is, at least, partially mediated through increased invasion and migration of tumor cells.
Discussion
Reduced TGFbRII expression in human NSCLC is associated with more aggressive tumor behavior
In this study, we found that reduced TGFbRII expression is common in NSCLC and occurs more frequently in males, smokers, and tumors with SCC histology; this grouping of associations is not surprising given that lung SCCs are more common in males and are more strongly associated with tobacco exposure (35) ; however, this is the first description clearly linking reduced TGFbRII expression with smoking exposure. Consistent with previous reports that TGFbRII expression in NSCLC can be reduced through promoter methylation or microsatellite instability (8, 11), we found both reduced TGFbRII at both the mRNA and protein levels, suggesting that reduced TGFbRII expression occurs pretranslationally. We also show that reduced TGFbRII expression is associated with more aggressive NSCLC behavior including reduced differentiation, higher T stage, nodal metastases, and reduced patient survival. This is consistent with TGFbRII functioning as an NSCLC Supplementary Fig. S4A) tumor suppressor, although other molecules clearly also contribute to malignant progression. These associations suggest a causal role of TGFbRII reduction in NSCLC progression, which is further supported by our animal study in which TGFbRII deletion increases NSCLC development in vivo.
Targeting TGFbRII deletion to K5-positive airway cells promotes formation of multiple NSCLC subtypes
We targeted TGFbRII deletion to the conducting airway epithelium using a K5-driven, RU486-inducible Cre recombinase and tracheal RU486 (19, 21) . Because keratin expression in the lung is limited to basal cells which are thought to contain the SCC progenitor cell (4, 36), we expected these animals to develop exclusively SCCs. To our surprise, while these animals did develop some SCCs, they predominantly developed adenomas and adenocarcinomas. In the murine airway, K5/K14-positive basal cells function as stem cells or facultative progenitors capable of giving rise to multiple cell types (20, 37) ; our data suggest that K5-positive cells contain both adenocarcinoma and SCC progenitors.
TGFbRII deletion alone in the airway epithelium results in a very low incidence of lung tumors; this is consistent with the observation that targeting TGFbRII deletion to a large fraction of lung epithelial cells by adenoviral-delivered Cre recombinase (AdCre) also fails to initiate tumor formation (17) . In contrast, TGFbRII deletion markedly increases Kras-initiated lung tumor number and size, suggesting that intact TGFb signaling inhibits lung tumor growth and that TGFb signaling disruption increases both tumor initiation and progression. Increased proliferation and tumor size is likely driven by loss of TGFb-mediated growth inhibition whereas increased tumor multiplicity may be a result of impaired immune surveillance from increased TGFb. These data are consistent with TGFbRII function in other oncogene-initiated cancer models (13) (14) (15) (16) as well as a recent report showing that invasive lung adenocarcinoma is modeled by Kras activation and TGFbRII deletion targeted by AdCre (17) . Our data show that TGFbRII deletion in mice increases tumor number, tumor size, and the number of malignant lesions; these observations are consistent with our observation that reduced TGFbRII expression in human NSCLC is associated with more aggressive tumor behavior. Our study shows that in addition to abrogation of TGFb-induced growth arrest, TGFbRII loss also promotes tumor cell migration and invasion. Although Kras.TGFbRII À/À tumors had little evidence of epithelial-to-mesenchymal transition (EMT), we have previously shown that TGFbRII loss causes an EMT-independent migratory and invasive phenotype in keratinocytes (38) . Interestingly, deleting one TGFbRII allele had an effect similar to deleting both TGFbRII alleles, indicating that TGFbRII exhibits haploid insufficiency, and that a 50% reduction (i.e., roughly the amount used to score human NSCLCs) is sufficient to promote lung cancer growth. This is similar to what was observed in both a head and neck cancer model (14) and a pancreatic cancer model (13) , where deletion of a single TGFbRII allele caused intermediate phenotypes in terms of tumor penetrance or survival, respectively. In another study, TGFb1 haploid insufficiency also increased progression of Kras-initiated lung tumors and shortened survival (39) , suggesting that reduced TGFb signaling in tumor epithelial cells promotes lung tumor progression.
TGFbRII deletion in airway epithelia increases inflammation that could promote malignant progression In our mouse model, TGFbRII deletion increased TGFb1 ligand elaboration, BAL inflammation, and tumor-associated macrophages and lymphocytes. In human lung cancer samples, reduced TGFbRII expression was associated with increased lymphocyte infiltration but not with increased macrophage infiltration. Because macrophages are recruited to areas of tissue damage, it is possible that macrophage infiltration in human lung samples may predominantly be driven by environmental factors (e.g., smoking) as opposed to reduced TGFbRII expression. In contrast, increased TGFb1 ligand produced by TGFbRII-negative tumors may recruit other inflammatory cells, for example, CD3-positive T lymphocytes, to the local environment where these cells could promote lung tumor progression (40) . Supporting this notion, increased lymphocyte infiltration (of CD4 cells, CD8 cells, and B cells) was also reported with AdCre-mediated Kras.TGFbRII À/À lung tumorigenesis (17) . In contrast to AdCre-mediated targeting that likely affects multiple cell types, targeting in our model was restricted to sporadic epithelial cells, thus inflammation was likely a result of secreted proinflammatory cytokines/chemokines, such as TGFb1, by targeted epithelial cells. TGFb1 can recruit myeloid cells (16) and induce development of regulatory T cells and T-helper (T H ) 17 lymphocytes (41), all of which can facilitate tumor growth. However, the paracrine effects of inflammatory cytokines in our model were insufficient to elicit the intense fibroblastic stromal response seen in AdCre-initiated because the lung has a higher oxygen tension that limits the need for tumor neovascularization, particularly of small tumors.
In summary, our study shows that reduced TGFbRII expression in human NSCLC is a negative prognostic marker associated with more aggressive tumor behavior and worse clinical outcome. In addition, TGFbRII loss plays a causal role in promoting the development of multiple NSCLC subtypes. Our study should instigate investigation into mechanisms underlying the effects of reduced TGFbRII expression on both tumor epithelium and tumor stroma. This could potentially facilitate selection of patients for therapies targeting events downstream of TGFbRII loss.
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